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Transthyretin cardiomyopathy (TTR-CM) is a rare, life-threatening disease 
characterized by the accumulation of amyloid fibrils of misfolded transthyretin protein in 
the heart.1 The natural history of TTR-CM is not well characterized with only one small 
multicenter longitudinal trial conducted2 along with a few single-center studies in larger 
but still relatively small populations (~100–300 patients).3-5 Given the relative paucity of 
data available on the natural history of TTR-CM, large-scale trials to study the efficacy 
and safety of a treatment must be designed with little prior knowledge or precedent for 
choosing endpoints, duration of study, or statistical considerations in a relatively rare 
disease. The purpose of this review is to provide a brief overview of TTR-CM and to 
present the rationale behind the design of the Transthyretin Cardiomyopathy Tafamidis 
clinical trial (ATTR-ACT; NCT01994889), a Phase 3 double-blind, placebo-controlled 
study of tafamidis meglumine in the treatment of TTR-CM that began enrollment in 
December 2013. 
Transthyretin and TTR Amyloidosis 
Transthyretin (TTR; also referred to as pre-albumin) is a 127-amino acid protein, 
primarily synthesized in the liver, that forms a 55 kDa homotetramer to transport 
thyroxine and retinol-binding protein-retinol (vitamin A) complex.6,7 The native TTR 
homotetramer can dissociate into monomers that can misfold and ultimately form 
amyloid fibrils.8 Various mutations of the TTR gene are associated with an increased 
rate of tetramer dissociation, which is thought to be the rate-limiting step in 
amyloidogenesis.9,10  
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TTR amyloidosis is a rare disease that occurs when TTR amyloid fibrils 
aggregate and deposit in various tissues.11,12 Presenting symptoms and disease course 
are highly variable and influenced by the underlying TTR mutation, age of the affected 
individual, gender, and geographic location.13-15 Typical disease manifestations include 
severe disabling autonomic and sensorimotor disturbance, cardiomyopathy, glaucoma, 
vitreous opacities, and gastrointestinal, renal, and urogenital dysfunction. Two 
phenotypic presentations of the disease predominate: transthyretin familial amyloid 
polyneuropathy (TTR-FAP), which primarily affects the peripheral nerves, and TTR-CM, 
which primarily affects the heart, although there is a wide overlap of these phenotypes.  
Transthyretin Cardiomyopathy 
TTR-CM can be hereditary or non-hereditary. More than 100 TTR mutations have been 
identified, at least 22 of which are mostly associated with TTR-CM.16-18 The valine 122 
to isoleucine (Val122Ile) is the most common TTR-CM variant, with a prevalence of 
about 3–4% in the African-American population.19 The non-hereditary form of the 
disease is caused by aggregation of the wild-type TTR protein and has been previously 
referred to as senile systemic amyloidosis. In this non-hereditary form, wild-type TTR 
forms amyloid fibrils, and deposits primarily in heart tissue. The epidemiology of TTR-
CM is not well characterized but the disease is increasingly diagnosed at referral 
centers, which may be related to an aging population and the greater use of non-
invasive cardiac imaging techniques such as cardiac magnetic resonance imaging and 
99mTc-phosphate scintigraphy.20 Based on the frequency of the Val122Ile TTR allele 
and US census data, up to 100,000 to 150,000 older African-Americans are estimated 
to be affected by TTR-CM.21 Recent studies in patients with heart failure with preserved 
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ejection fraction (HFpEF) found that TTR amyloid deposits accounted for a significant 
number of HFpEF cases.22,23 The clinical significance of subclinical wild-type TTR 
amyloid deposits in the heart in elderly patients with HFpEF has yet to be determined, 
but these deposits could be contributing to the overall HFpEF syndrome in some elderly 
patients with HFpEF who do not have overt, clinically apparent cardiac amyloidosis.  
TTR-CM is a late-onset disease with symptoms typically manifesting in patients 
aged 60 years or older.2 Cardiac symptoms include dyspnea on exertion, fatigue and 
effort intolerance, orthostatic hypotension, and syncope.24 Conduction abnormalities 
including bundle branch block, atrioventricular block, sinoatrial disease, and atrial 
fibrillation are frequent.24 Objective measures of cardiac involvement include an 
abnormal electrocardiogram with low QRS voltage, pseudoinfarction patterns, and 
discordance between left ventricular wall thickness and QRS voltage; left and right 
ventricular wall thickening, severely reduced systolic and diastolic longitudinal tissue 
velocities, and severely reduced absolute global longitudinal strain (with relative apical 
sparing) demonstrated on echocardiography; predominant subendocardial delayed 
enhancement with difficulty nulling the myocardium on cardiac magnetic resonance 
imaging; and elevated plasma troponin and brain natriuretic peptides.25,26  
Until recently, TTR-CM was definitively diagnosed by histological identification of 
amyloid deposits in a cardiac biopsy sample, but non-invasive diagnostic methods are 
being explored.24 Nuclear scintigraphy using 99mTechnetium (Tc)- labeled 3,3-
diphosphono-1,2-propanodicarboxylic acid (DPD), 99mTc-labeled pyrophosphate 
(PYP), or 99mTc-labeled hydroxymethylene diphosphonate (HMDP) to accurately 
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diagnose TTR-CM has been proposed as a non-invasive method for diagnosing 
suspected amyloidosis.27 A study of patients with diagnosed cardiac amyloidosis 
showed that 99mTc-PYP cardiac imaging was able to differentiate between light-chain 
(AL) cardiac amyloidosis and TTR-CM in patients with normal light-chains and high 
99mTc-PYP uptake.28 A quantitative heart to contralateral lung ratio, which can be 
calculated from 99mTc-PYP imaging, of ≥1.6 was associated with worse survival in 
patients with TTR-CM.29 This non-invasive diagnostic method is able to identify early-
stage TTR-CM in asymptomatic carriers of variant TTR30 and thus is able to diagnose 
TTR-CM without the complications that can arise with cardiac biopsy, and may be 
contributing to the increasing recognition of this disease. 
Prognosis is poor in patients with TTR-CM. In patients with wild-type TTR-CM, 
estimates of median survival time range from approximately 26 months to 67 months 
from diagnosis2-4,31,32 and 72 months from symptom onset.5 Patients with Val122Ile 
TTR-CM have median survival time from diagnosis ranging from approximately 36 
months to 43 months.2,31,32 Death in most patients with cardiac amyloidosis is from 
sudden death and progressive pump failure.24 
Current Treatments for TTR-CM 
Symptom management has been the mainstay of therapy for TTR-CM patients with the 
use of diuretics for symptoms of heart failure and pacemaker placement for 
bradycardia.24 The only disease-modifying treatment option currently available for TTR-
CM patients is organ transplantation in patients with genetic forms of the disease.24 
Liver transplantation removes the primary production site of the TTR protein and, 
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theoretically, removes the source of amyloidogenic TTR. For some patients with wild-
type TTR-CM, heart transplants may be appropriate depending on the severity of 
cardiac involvement.33,34 This treatment is generally not feasible given the scarcity of 
organs and advanced age of affected patients in addition to the surgical risk and need 
for life-long immunosuppression.24 Additionally, evidence suggests that the disease can 
progress after liver transplant due to deposition of wild-type TTR amyloid fibrils.35 
Diflunisal, a nonsteroidal anti-inflammatory drug, was shown to increase serum TTR 
stability in 37 patients with TTR-FAP36 and, in a subsequent clinical trial in 130 patients, 
to reduce the rate of progression of neurological impairment over 2 years.37 In a cohort 
of 13 patients with ATTR-CM, a single-arm, open-label cohort study suggested that at a 
low dose (250 mg, orally twice a day), and with careful monitoring, diflunisal along with 
a prophylactic proton pump inhibitor (PPI) could be safely administered to selected 
patients, although an association was observed between chronic diflunisal use and 
adverse changes in renal function, suggesting that severe renal dysfunction may be 
prohibitive to diflunisal administration.38 Diflunisal is not approved to treat TTR-FAP or 
TTR-CM and, as a nonsteroidal anti-inflammatory drug, its chronic use may present a 
safety concern for patients at risk of renal, gastrointestinal, or cardiovascular disease. At 
present, there are no approved pharmacologic therapies that have been shown to 
improve survival in TTR-CM.  
Mechanism and Rationale for Tafamidis Therapy in TTR-CM 
Tafamidis is an oral-administered small molecule approved in parts of Europe, Asia, and 
Latin America to delay neurologic progression of TTR-FAP. Tafamidis binds to TTR at 
the thyroxine binding sites and inhibits TTR tetramer dissociation, the rate-limiting step 
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in the amyloidogenic process.39 By stabilizing the tetrameric native state of TTR, 
tafamidis increases the activation barrier associated with tetramer dissociation. It has 
been shown to slow fibril formation in vitro40 and in TTR variants associated with cardiac 
phenotypes, selectively binds and stabilizes TTR tetramers from plasma.41,42 Using a 
validated immunoturbidimetric assay, an analysis of TTR from patient plasma found that 
tafamidis stabilized wild-type and Val122Ile TTR tetramer in 34 of 35 (97.1%) patients at 
the end of 6 weeks and 28 of 35 (88%) at the end 12 months of treatment.41  
Clinical trial data have demonstrated long-term efficacy and safety of tafamidis in 
the treatment of TTR-FAP.42-46 In a randomized, placebo-controlled trial in patients with 
TTR-FAP, those in the intent-to-treat population who received tafamidis demonstrated 
52% less neurologic deterioration after 18 months of treatment than patients who 
received placebo.45 Based on these and other data, it was hypothesized that tafamidis 
might also slow or halt the progression of TTR-CM and in a Phase 2 open-label, 
interventional study, 12 months of tafamidis 20 mg given once daily to patients with 
Val122Ile and wild-type TTR-CM stabilized disease progression with an acceptable 
safety profile.41  
Design and Rationale of ATTR-ACT 
The Phase 3 ATTR-ACT study is an international, multicenter, double-blind, placebo-
controlled, randomized clinical trial. Enrollment began in December 2013 and was 
completed in August 2015; the study is ongoing. The primary objective is to evaluate the 
efficacy, safety, and tolerability of tafamidis (20 mg or 80 mg orally once daily) in 
comparison with placebo for the treatment of TTR-CM. Patients completing this study 
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will be given the option of continuing into a long-term extension study of tafamidis. The 
appropriate Institutional Review Board and Independent Ethics Committee approvals 
were secured before start of the study.  
Study Design and Dose Selection 
This study utilizes a three-arm, parallel, placebo-controlled, randomized study design 
with a 30-month double-blind treatment phase (Figure 1). The duration of the treatment 
period was based on the reported median survival time from diagnosis for TTR-CM 
patients available at the time of study initiation.2-4,31,32 
The 20 mg dose of tafamidis has been successfully used previously in both 
polyneuropathy and cardiomyopathy clinical trials.11,42,45,47 While this dose was shown to 
stabilize wild-type and Val122Ile TTR tetramer in the majority of patients after 12 
months treatment using an immunoturbidity assay,41 a greater range of tafamidis 
exposures have been used to assess TTR stabilization in healthy volunteers and in 
ATTR cardiac amyloid subjects using a subunit exchange assay,48 demonstrating the 
potential for a greater degree of stabilization at TTR:tafamidis stoichiometry values 
greater than those achieved at the 20 mg dose.49 The inclusion of an 80 mg dose, which 
results in near maximal TTR stabilization, permits exploration of a higher dose to assess 
efficacy and safety of adequately separated doses.50 In the event that patients 
experience adverse events that could impact dosing adherence, they will receive a 
blinded dose reduction. Patients receiving the 80 mg dose will be reassigned to the 40 
mg dose, which was empirically selected in an effort to allow patients who could not 
tolerate the higher dose to potentially remain in the study at a dose higher than 20 mg. 
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Patients receiving either placebo or the 20 mg dose of tafamidis will be maintained on 
that dose.  
Patient Population 
The inclusion criteria were chosen to select patients with a predominant cardiac 
phenotype; specifically, documented TTR-CM with either wild-type TTR or a variant 
TTR genotype (assessed by genotyping, with patients with concurrent monoclonal 
gammopathy of undetermined significance requiring a confirmatory test using mass 
spectrometry or immunohistochemistry), the presence of TTR amyloid deposits in 
biopsy tissue, age ≥18 to ≤90 years, and a history of heart failure evidenced by at least 
one prior hospitalization for heart failure or clinical evidence of heart failure (without 
hospitalization) requiring diuretics. TTR precursor protein identification can also be 
made by immunohistochemistry or mass spectrometry. Nuclear scintigraphy using 
99mTc-labeled PYP, HMDP, or DPD is used as a confirmatory test of TTR 
involvement.27  
A 6-minute walk test (6MWT) of >100 meters is also required for inclusion, so patients 
with advanced stage disease (New York Heart Association [NYHA] functional class IV) 
who are unlikely to benefit are not enrolled. As patients with variant TTR-CM are 
potentially more likely to have a mixed neurologic/cardiac phenotype, they may also be 
more likely to experience difficulties completing this test. As such, and also to account 
for any other variation between groups, the study intends to enroll a minimum of 30% 
variant TTR-CM patients and 30% wild-type TTR-CM patients. To ensure patients 
included in the study have a cardiac cause for their symptoms and to ensure a sufficient 
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event rate within the 30-month duration of the study, a plasma N-terminal prohormone 
of brain natriuretic peptide (NT-proBNP) concentration ≥600 pg/mL is required for 
enrollment.  
Major exclusion criteria include a confirmed diagnosis of light chain (AL) 
amyloidosis, previous treatment with tafamidis, an estimated glomerular filtration rate of 
<25 mL/min/1.73 m2, and concurrent treatment with non-steroidal anti-inflammatory 
drugs, tauroursodeoxycholate and doxycycline, calcium channel blockers, or digitalis. 
Additional exclusion criteria include modified-body mass index (mBMI) of <600 
kg/m2•g/L, and heart failure not due to TTR-CM. 
Study Assessments 
The efficacy assessments (Table 1) include all-cause mortality and frequency of 
cardiovascular-related hospitalization, which includes heart failure, arrhythmia, 
myocardial infarction, and stroke as well as other cardiovascular-related events. Quality 
of life assessments include the Kansas City Cardiomyopathy Questionnaire (KCCQ) to 
assess the functional and clinical limitations of patients with heart failure; the EuroQOL-
5 Dimension-3 Level, a self-administered generic health status instrument to assess 
quality of life; and the Patient Global Assessment to assess overall health status. In 
addition, disease progression is measured using the 6MWT and the NYHA functional 
classification. These assessments are conducted at baseline, at 6-month intervals, and 
at the end of the study or at the time of patient discontinuation. For subjects who 
discontinue prior to Month 30, a vital status follow-up is conducted at Month 30 to obtain 
their mortality status for use in the analysis. Other efficacy assessments include TTR 
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stabilization, plasma concentrations of TTR oligomer and troponin I and mBMI which 
serves as an index of nutritional status. NT-proBNP and troponin T are measured since 
they are associated with survival in wild-type TTR-CM.4 To monitor compliance to the 
protocol, pharmacokinetic samples to determine tafamidis and diflunisal concentrations 
are also collected. Diflunisal is a nonsteroidal anti-inflammatory drug, not approved to 
treat TTR-FAP, but has been shown to slow TTR-FAP progression.37  
Safety assessments (Table 1) include incidence of adverse events, vital signs, 
echocardiograms, and clinical laboratory tests. These assessments are conducted at 
baseline and at clinic visits until the end of the study or patient discontinuation. 
Study Endpoints 
The primary analysis will use a hierarchical combination of all-cause mortality and 
frequency of cardiovascular-related hospitalizations (defined as a non-elective 
admission to an acute care setting for medical therapy for cardiovascular-related 
morbidity resulting in at least a 24-hour stay). Key secondary endpoints comprise the 
change from baseline to Month 30 in the 6MWT and KCCQ-overall score. Additional 
secondary and exploratory endpoints will be analyzed. This protocol utilizes an Endpoint 
Adjudication Committee (EAC) to determine whether certain investigator-reported 
events meet the definition of cardiovascular-related efficacy endpoints, using pre-
defined endpoint criteria. The EAC is independent of the study sponsor.  
Statistical Considerations 
The sample size is based on findings from previous studies and an understanding of 
current clinical outcomes in this population, and the uncertainty of the assumptions 
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derived from these limited data available at the time of study initiation.2,45 Sample size 
assumptions include an all-cause mortality rate of 12.5% for the tafamidis group and 
25.0% for placebo group (i.e. 50% reduction in mortality with treatment) and an average 
cardiovascular-related hospitalization frequency of 1.5 for the tafamidis group and 2.5 
for the placebo group over 30 months. For a significance level of 0.05 (two-sided test), a 
sample size of 300 (assuming pooled tafamidis 20 mg and tafamidis 80 mg versus 
placebo) yields a power >90%. To mitigate the uncertainty around the study design 
assumptions due to the lack of data, target sample size was increased from 300 to 400 
planned.  
Patients were allocated to the 3 arms of the study in a 2:1:2 ratio (placebo:20 
mg:80 mg). Patients were stratified by baseline NYHA functional class (NYHA Class I 
and NYHA Classes II and III combined) and TTR genotype (variant or wild-type) with a 
minimum of 30% variant and 30% wild-type across the overall study. The stratification 
factors were utilized at randomization.  
The primary analysis uses a hierarchical combination of all-cause mortality and 
frequency of cardiovascular-related hospitalizations over the duration of the trial. Heart 
transplant, heart and liver transplant, and implantation of a cardiac mechanical assist 
device are treated as death for this analysis. The primary analysis pools the patients in 
the tafamidis 20 mg and tafamidis 80 mg groups (including patients in the 80 mg group 
that may have had a dose reduction to 40 mg) into one group. This pooled tafamidis 
group is to be compared with the placebo group using the Finkelstein-Schoenfeld 
method.  
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The Finkelstein-Schoenfeld method51 (Table 2), increases the sensitivity and 
power of the analysis while also preserving the importance of the all-cause mortality 
endpoint. The test is based on the principle that each patient in the clinical study is 
compared with every other patient within each stratum in a pair-wise manner. The 
method recognizes the higher importance of all-cause mortality. The pair-wise 
comparison proceeds in a hierarchical fashion using all-cause mortality first, assigning a 
+1 to the “better” patients and a –1 to the “worse” patients. The test statistic is based on 
the sum of these scores within each strata and then summed across the 4 strata. The 
null hypothesis for the primary analysis is that neither all-cause mortality nor frequency 
of cardiovascular-related hospitalizations is different between the tafamidis and placebo 
treatment groups. The corresponding alternative hypothesis is that at least one and 
possibly both mortality and frequency of cardiovascular-related hospitalizations are 
different between the tafamidis and placebo treatment groups. 
The key secondary endpoints are evaluated using a mixed model repeated 
measures analysis of covariance with an unstructured covariance matrix (or as 
appropriate); center and patient-within-center as random effects; treatment, visit, TTR 
genotype (variant and wild-type), and visit-by-treatment interaction as fixed effects and 
baseline score as covariate. As a secondary analysis, the components of the primary 
endpoint (i.e. all-cause mortality and frequency of cardiovascular-related 
hospitalizations) are analyzed separately.  
All randomized patients who receive at least 1 dose of study treatment are 
included in the safety analysis. All adverse events observed from the time of first dosing 
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with study medication (at randomization) until the end of study participation are included 
in the safety analysis. Adverse events that occur during treatment are reported 
separately if the event occurred prior to randomization. All adverse events are coded 
according to the Medical Dictionary for Regulatory Activities (MedDRA) and 
summarized by treatment group. 
Discussion 
This trial is the largest multicenter investigation of a treatment for TTR-CM, a condition 
associated with high mortality and symptom burden for which there are no approved 
disease-modifying pharmacotherapies. The primary objective of the study is to evaluate 
the efficacy of tafamidis treatment compared with placebo in patients with biopsy-
confirmed TTR-CM. The safety and tolerability of 2 tafamidis doses, 20 mg and 80 mg, 
also will be assessed.  
Enrollment for this trial began in December 2013 and was completed in 
approximately 1.5 years, which is relatively rapid compared with other heart failure 
studies.52,53 There are a few potential reasons for this expedited enrollment, including a 
low screen failure rate, clear objective criteria for diagnosis of TTR-CM, a lack of 
available treatments, and high mortality rate in this disease. Access to the study drug in 
the long-term extension study upon completion of this study also may have encouraged 
patient enrollment. 
The progressive nature of some rare diseases, like TTR-CM, makes clinical 
requirements of a disease-modifying therapy more relevant to the stage of disease (i.e. 
early stage versus late stage).54 Since tafamidis is predicted to delay disease 
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progression by stabilizing the TTR tetramer, it is necessary to balance selection of a 
cohort at an early disease stage with one that has event rates sufficient to compare 
outcomes with the placebo group. It is anticipated that the stringent inclusion and 
exclusion criteria of this trial combined with the high enrollment rate provide sufficient 
data to allow meaningful interpretation of the results. 
Well-characterized endpoints to determine efficacy of a pharmacologic treatment 
are difficult to define for rare diseases. Additionally, endpoints that are clinically 
meaningful to patients and regulators must be chosen. The endpoints for the ATTR-
ACT study were chosen using data from the available natural history studies and clinical 
trials.2-5,41 In rare disease studies where there are small patient populations, the 
Finkelstein-Schoenfeld method can increase the sensitivity and power of the analysis 
while also preserving the importance of the all-cause mortality endpoint. This method is 
used in the present study and will help ensure that the selected endpoints allow clear 
conclusions about the effectiveness of tafamidis in treating TTR-CM.  
 Limitations of this study include the following: the limited availability of 
information on the natural history of cardiac amyloidosis which poses challenges in 
designing a robust clinical trial to evaluate treatment, the impact of multiple chronic 
conditions prevalent in an aging study population on outcomes of interest (QOL and 
submaximal functional capacity), and mobility limitations may lead to high dropout rates. 
The mixed neurologic/cardiac phenotype of some TTR-CM patients, especially those 
with mutations, may also impact efficacy endpoints such as mobility measures like the 
6MWT. The study design aims to minimize this potential limitation by ensuring a 
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minimum of 30% variant and 30% wild-type patients in the study. Patients with NYHA 
Class II/III may also be overrepresented in the study and preclude treatment effects 
given the extent of disease progression. The clear inclusion criteria may reduce the 
impact of this limitation. 
Summary 
The ATTR-ACT study is designed to evaluate clinically meaningful endpoints for 
patients, families, and regulators and will provide important insights into the efficacy and 
safety of tafamidis for the treatment of TTR-CM. The design of this study will also inform 
other studies in rare disease that must manage similar challenges in design and 
recruitment. 
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Figure 1 Study design 
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[[TABLES]] 
Table 1. Assessments for Efficacy and Safety 
Efficacy  
All-cause mortality and cardiovascular-related hospitalization 
Kansas City Cardiomyopathy Questionnaire 
6-Minute Walk Test  
EuroQOL-5 Dimensions-3 Level 
Patient Global Assessment  
Modified Body Mass Index 
TTR Stabilization, oligomer concentration, and concentration measurements 
New York Heart Association Functional Classification 
N-Terminal Prohormone of Brain Natriuretic Peptide 
Troponin I 
Echocardiograms 
Electrocardiograms 
Safety 
Adverse Events 
Medical History 
Physical Examinations  
Vital Signs 
Clinical Laboratory Tests 
TTR indicates transthyretin. 
 
 
 
27 
 
Table 2. Finkelstein-Schoenfeld Scoring Algorithm 
In each scenario, a pair-wise comparison of patients is made by first taking mortality into 
account. If there is a clear difference (scenario 1), then a score is assigned. If there is 
no difference (scenario 2), then survival time is considered and a score is assigned if 
there is a clear difference between the patients. If there is no difference between the 2 
patients in survival time, then the frequency of cardiovascular hospitalization (scenario 
3) is considered and a score is assigned. If there is no difference in cardiovascular 
hospitalization frequency between the 2 patients (scenario 4), then no score is 
assigned. If there is missing information (scenario 5 and 6), then the next assessment in 
the hierarchy is considered. 
Scenario Mortality Survival Time 
Cardiovascular 
Hospitalization 
Frequency 
Score 
1 
Dead - - –1 
Alive - - +1 
2 
Dead Low - –1 
Dead High - +1 
3 
Dead tied High –1 
Dead tied Low +1 
4 
Dead tied tied 0 
Dead tied tied 0 
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5 
Alive - High –1 
Alive - Low +1 
6 
Alive - tied 0 
Alive - tied 0 
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[[FIGURE]] 
Figure 1 Study design 
 
 
QD indicates once daily. 
